"I love EVOTAZ® (atazanavir/cobicistat) HIV Treatment | For Healthcare Providers"

2022-10-12 11:30:40

This site is intended for US Healthcare Professionals only.ResourcesFor Patients and Caregivers Resources.img_txt { display: inline-flex;}.dPage.res { margin: 5px 3px 0px 3px; color: #000; font: normal 12px arial;}a#resourcesid { text-decoration: none;}.deskbmslogo{margin-top: -5px;}p.circle.dPage{margin:2px;}.mobtext{color:#000;float:right;font-family: "open_sansregular", arial;font-size:12px;margin-top:6px;text-decoration:none;}.circle{border-radius: 50%; width: 20px; height: 20px; background-color: #000;position: relative;float:right;margin:5px;}.circle::after { content: " "; position: absolute; display: block; background-color: #fff; height: 2px; margin-top: -5px; top: 65%; left: 4px; right: 5px; z-index: 9;}.circle::before { content: " "; position: absolute; display: block; background-color: #fff; width: 2px; margin-left: -4.5px; left: 63%; top: 4px; bottom: 5px; z-index: 9;} MENUHomeEfficacy DataVirologic Suppression RatesEfficacy by Viral LoadEfficacy by CD4+Study DesignResistance DataPharmacokinetic ProfileSafety & TolerabilitySafety ProfileEvaluation of LipidsGI Side EffectsDosing Virologic SuppressionRates US Full Prescribing Information for EVOTAZ and REYATAZ| Patient InformationProduct LinksUS Full Prescribing Information for EVOTAZUS Full Prescribing Information for REYATAZPatient InformationIndicationINDICATIONS for EVOTAZ® (atazanavir and cobicistat) and REYATAZ® (atazanavir)(200 mg/300 mg capsules)EVOTAZ is a fixed dose combination of atazanavir and cobicistat, and is indicated for use with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.REYATAZ is indicated for use with other antiretroviral agents for the treatment of HIV-1 infection for patients 3months and older weighing at least 5 kg.Limitations of UseUse of EVOTAZ or REYATAZ/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutionsREYATAZ is not recommended for use in pediatric patients 0.4 mg/dL from baseline should be closely monitored for renal safetyNew Onset or Worsening Renal Impairment when used with tenofovir disoproxil fumarate: Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported when cobicistat was used with tenofovir disoproxil fumarate(tenofovir DF)Coadministration of EVOTAZ and tenofovirDF is not recommended in patients who have an estimated CrCl